Picture of Marinomed Biotech AG logo

MARI Marinomed Biotech AG Share Price

0.000.00%
at flag iconLast trade - 00:00
HealthcareAdventurousMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-18.62%
3m-36.43%
6m-62.19%
1yr-72.02%
Volume Change (%)
10d/3m+52.68%
Price vs... (%)
52w High-70.31%
50d MA-20.26%
200d MA-53.1%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-58.7%
Return on Equityn/a
Operating Margin-85.06%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Marinomed Biotech AG EPS forecast chart

Profile Summary

Marinomed Biotech AG, formerly known as Marinomed Biotechnologie GmbH is a Austria-based biopharmaceutical company. The company develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients. This technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. The company also develops treatments for type I allergies and autoimmune diseases. The company is a spin-off from the University of Veterinary Medicine, Vienna.

Directors

Last Annual
December 31st, 2023
Last Interim
March 31st, 2024
Incorporated
December 31st, 2006
Public Since
February 1st, 2019
No. of Employees
47
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
at flag iconVienna Stock Exchange
Shares in Issue
1,540,530
Blurred out image of a map
Address
Hovengasse 25, KORNEUBURG, 2100
Web
https://www.marinomed.com/
Phone
+43 226290300
Contact
Stephanie Kniep
Auditors
Bdo Austria GmbH Wirtschaftsprufungs Und Steuerberatungsgese

MARI Share Price Performance

Upcoming Events for MARI

Q2 2024 Marinomed Biotech AG Earnings Release

Q3 2024 Marinomed Biotech AG Earnings Release

FAQ